The recent trial flop for Ztalmy, this time in tuberous sclerosis complex (TSC)-associated seizures, leaves the company in a ...
Marinus Pharmaceuticals (MRNS) stock was downgraded at TD Cowen and Truist after a Phase 3 failure for lead asset, ganaxolone ...
On Thursday, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) stock plunged after the company revealed disappointing data from the ...
Marinus Pharmaceuticals shares plunged nearly 80% to a new all-time low on Thursday after the pharmaceutical company said it is cutting jobs and exploring strategic options following the failure of ...
The British pharma is making what it calls its largest U.S. manufacturing investment. Elsewhere, AbbVie expanded a ...
MarketBeat on MSN12d
Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?Detailed price information for Marinus Pharma CS (MRNS-Q) from The Globe and Mail including charting and trades.
Ganaxolone is a neuroactive steroid GABAA receptor positive modulator that targets the brain’s anti-seizure response.
Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Marinus Pharmaceuticals (MRNS) to $4 from $13 and keeps an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback